WorthPointe, LLC: SCHO position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of WorthPointe, LLC on SCHO, newest first. How the timeline and the estimate are built.
WorthPointe, LLC held 46,491 SCHO shares at 2026-06-30 per its 13F-HR filed 2026-07-31.
the latest 13F is the newest step
- period ended2026-06-3013F 46,491 sharesChange vs previous 13F -35,426 shares
0.28% of the 13F portfolio, value $1,122,295.
13F-HR 0001172661-26-002988 filed by WorthPointe, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2026-03-3113F 81,917 sharesChange vs previous 13F -58,258 shares
0.54% of the 13F portfolio, value $1,988,118.
13F-HR 0001172661-26-001733 filed by WorthPointe, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-12-3113F 140,175 sharesChange vs previous 13F +130,923 shares
0.9% of the 13F portfolio, value $3,416,061.
13F-HR 0001172661-26-000300 filed by WorthPointe, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-09-3013F 9,252 sharesChange vs previous 13F -567 shares
0.08% of the 13F portfolio, value $225,749.
13F-HR 0001172661-25-004324 filed by WorthPointe, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-06-3013F 9,819 sharesChange vs previous 13F +62 shares
0.1% of the 13F portfolio, value $239,387.
13F-HR 0001172661-25-002895 filed by WorthPointe, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2025-03-3113F 9,757 sharesChange vs previous 13F not available
0.11% of the 13F portfolio, value $237,485.
13F-HR 0001172661-25-001581 filed by WorthPointe, LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).